Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer

  1. Levy, B.P.
  2. Giaccone, G.
  3. Besse, B.
  4. Felip, E.
  5. Garassino, M.C.
  6. Domine Gomez, M.
  7. Garrido, P.
  8. Piperdi, B.
  9. Ponce-Aix, S.
  10. Menezes, D.
  11. MacBeth, K.J.
  12. Risueño, A.
  13. Slepetis, R.
  14. Wu, X.
  15. Fandi, A.
  16. Paz-Ares, L.
Revue:
European Journal of Cancer

ISSN: 1879-0852 0959-8049

Année de publication: 2019

Volumen: 108

Pages: 120-128

Type: Article

DOI: 10.1016/J.EJCA.2018.11.028 GOOGLE SCHOLAR